Jie Pang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jie Pang has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
Lihua Wang
Hangzhou Linping Hospital of Traditional Chinese Medicine Hangzhou Zhejiang China
1 shared publicationLinyan Qian
Heart Center, Department of Cardiovascular Medicine, Zhejiang Provincical People’s Hospital (Affiliated People’s Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, China
1 shared publication- Ping Lv
School of Electronics and Information, Central South University, Changsha, China
1 shared publication - Qiang Xu
State Key Laboratory of Traditional Chinese Medicine Syndrome, The First Clinical Medical College of Guangzhou University of Chinese Medicine, Guangzhou, People’s Republic of China
1 shared publication - Qingcheng Wang
Hangzhou Linping Hospital of Traditional Chinese Medicine Hangzhou Zhejiang China
1 shared publication - Weili You
Department of Pharmacy Affiliated Lianyungang Hospital of Xuzhou Medical University/First People's Hospital of Lianyungang Lianyungang Jiangsu Province China
1 shared publication
Latest Publications
- Open Access
- 25 October 2024
- Published by Wiley in Annals of Noninvasive Electrocardiology
- Vol. 29 (6) , e70015
Biotronik Implantable Cardioverter Defibrillator for Measurement of Intrathoracic Impedance: A Report of Two Cases
Objectives: Two patients were received ICDs (Biotronic Iforia7 VR‐TDX). Holter analysis revealed pacing spikes, which occurred regularly at 100 ms intervals following QRS complexes, with consecutive 1024 test pulses at hourly intervals during a specific time, and the VP was 0%.Methods: By analyzing the dynamic electrocardiogram and consulting relevant literature, it was found that this is a feature of the ICD that measures thoracic impedance.Results: This phenomenon is a special function for the purpose of transthoracic impedance measurement, which can monitor the heart failure.Conclusions: This phenomenon should not be regarded as an interference signal or an abnormal sign of pacemaker malfunction.
- 25 October 2024
- Published by Wiley in Annals of Noninvasive Electrocardiology
- Vol. 29 (6) , e70015
Open AccessBiotronik Implantable Cardioverter Defibrillator for Measurement of Intrathoracic Impedance: A Report of Two Cases
Objectives: Two patients were received ICDs (Biotronic Iforia7 VR‐TDX). Holter analysis revealed pacing spikes, which occurred regularly at 100 ms intervals following QRS complexes, with consecutive 1024 test pulses at hourly intervals during a specific time, and the VP was 0%.Methods: By analyzing the dynamic electrocardiogram and consulting relevant literature, it was found that this is a feature of the ICD that measures thoracic impedance.Results: This phenomenon is a special function for the purpose of transthoracic impedance measurement, which can monitor the heart failure.Conclusions: This phenomenon should not be regarded as an interference signal or an abnormal sign of pacemaker malfunction.
- Open Access
- 30 October 2023
- Published by Taylor & Francis in Clinical and Experimental Hypertension
- Vol. 45 (1) , 2272581
TyG index is a predictor of all-cause mortality during the long-term follow-up in middle-aged and elderly with hypertension
The triglyceride and glucose (TyG) index has been found to be significantly associated with a higher risk of mortality. However, there has been a lack of studies exploring the specific relationship between the TyG index and all-cause and cardiovascular mortality among middle-aged and elderly with hypertension. A total of 3,614 participants with hypertension were enrolled from the National Health and Nutrition Examination Survey. The TyG index was calculated using the formula log [fasting triglycerides (mg/dL) x fasting glucose (mg/dL)/2]. The Cox proportional hazard ratios were used to evaluate the association between the TyG index and the risk of mortality. Over a follow-up period of 7.87 years, 991 all-cause death and 189 cardiovascular deaths occurred. Compared with the reference quartile, the multivariate-adjusted hazard ratios and 95% confidence intervals were 1.28 (1.07-1.53; p = .006) in the fourth quartile for all-cause mortality and 0.63 (0.42-0.96; p = .031) in the second quartile for cardiovascular mortality. Dose-response analysis indicated an L-shaped relationship. The TyG index exhibited an L-shaped association with the risk of all-cause mortality among middle-aged and elderly with hypertension.
- 30 October 2023
- Published by Taylor & Francis in Clinical and Experimental Hypertension
- Vol. 45 (1) , 2272581
Open AccessTyG index is a predictor of all-cause mortality during the long-term follow-up in middle-aged and elderly with hypertension
The triglyceride and glucose (TyG) index has been found to be significantly associated with a higher risk of mortality. However, there has been a lack of studies exploring the specific relationship between the TyG index and all-cause and cardiovascular mortality among middle-aged and elderly with hypertension. A total of 3,614 participants with hypertension were enrolled from the National Health and Nutrition Examination Survey. The TyG index was calculated using the formula log [fasting triglycerides (mg/dL) x fasting glucose (mg/dL)/2]. The Cox proportional hazard ratios were used to evaluate the association between the TyG index and the risk of mortality. Over a follow-up period of 7.87 years, 991 all-cause death and 189 cardiovascular deaths occurred. Compared with the reference quartile, the multivariate-adjusted hazard ratios and 95% confidence intervals were 1.28 (1.07-1.53; p = .006) in the fourth quartile for all-cause mortality and 0.63 (0.42-0.96; p = .031) in the second quartile for cardiovascular mortality. Dose-response analysis indicated an L-shaped relationship. The TyG index exhibited an L-shaped association with the risk of all-cause mortality among middle-aged and elderly with hypertension.
- 8 April 2021
- Published by Wiley in Biomedical Chromatography
- Vol. 35 (9) , e5139
Pharmacokinetics, bioavailability and metabolism of CC‐92480 in rat by liquid chromatography combined with electrospray ionization tandem mass spectrometry
CC‐92480 is a cereblon E3 ubiquitin ligase modulating drug with potent antimyeloma activity. In this study, we developed a sensitive UHPLC–MS/MS method for the determination of CC‐92480 in rat plasma. The plasma samples were prepared with acetonitrile and the samples were then separated on an Acquity BEH C18 column (2.1 × 50 mm, 1.7 μm) with water containing 0.1% formic acid (A) and acetonitrile (B) as mobile phase. The MS detection was performed using multiple reaction monitoring mode with precursor‐to‐product ion transitions at m/z 568.3 > 363.1 for CC‐92480 and m/z 441.2 > 138.1 for ibrutinib (internal standard). The assay showed excellent linearity over the concentration range of 1–1,000 ng/ml, with correlation coefficient >0.995. The method was further validated for selectivity, precision, accuracy, recovery and stability according to the US Food and Drug Administration's guideline. The validated method was successfully applied to the pharmacokinetic and bioavailability studies of CC‐92480 in rat plasma. Based on the pharmacokinetic results, the oral bioavailability of CC‐92480 was >63%. In addition, the circulating metabolites of CC‐92480 were detected by UHPLC–HRMS and the structures were proposed according to their accurate masses and fragment ions. The proposed metabolic pathways of CC‐92480 were oxidative dealkylation and amide hydrolysis.
- 8 April 2021
- Published by Wiley in Biomedical Chromatography
- Vol. 35 (9) , e5139
Pharmacokinetics, bioavailability and metabolism of CC‐92480 in rat by liquid chromatography combined with electrospray ionization tandem mass spectrometry
CC‐92480 is a cereblon E3 ubiquitin ligase modulating drug with potent antimyeloma activity. In this study, we developed a sensitive UHPLC–MS/MS method for the determination of CC‐92480 in rat plasma. The plasma samples were prepared with acetonitrile and the samples were then separated on an Acquity BEH C18 column (2.1 × 50 mm, 1.7 μm) with water containing 0.1% formic acid (A) and acetonitrile (B) as mobile phase. The MS detection was performed using multiple reaction monitoring mode with precursor‐to‐product ion transitions at m/z 568.3 > 363.1 for CC‐92480 and m/z 441.2 > 138.1 for ibrutinib (internal standard). The assay showed excellent linearity over the concentration range of 1–1,000 ng/ml, with correlation coefficient >0.995. The method was further validated for selectivity, precision, accuracy, recovery and stability according to the US Food and Drug Administration's guideline. The validated method was successfully applied to the pharmacokinetic and bioavailability studies of CC‐92480 in rat plasma. Based on the pharmacokinetic results, the oral bioavailability of CC‐92480 was >63%. In addition, the circulating metabolites of CC‐92480 were detected by UHPLC–HRMS and the structures were proposed according to their accurate masses and fragment ions. The proposed metabolic pathways of CC‐92480 were oxidative dealkylation and amide hydrolysis.